FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
17/01/2025
Voltar para busca
Dado oficial do USPTO
VECTAB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
17/01/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
01/08/2022
Data de registro
09/04/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/04/2024
Última transação
17/01/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
NL
Examinador
STEEL, ALYSSA
Unidade examinadora
N60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
VectorY B.V.
Representantes
Douglas T. Johnson Miller & Martin PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Viral systems comprised of viral vectors combined with antibodies; gene therapy systems comprised of viral vectors combined with antibodies; nucleic acid delivery systems being therapeutic agents for delivery to human tissue namely viral vectorsnon-viral vectorsgene therapy vectorsnucleic acid delivery vectorscells transformed by viral vectorsnon-viral vectorsgene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for the treatment neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for use in medical and clinical gene therapynucleic acid-based therapy and cell therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; clinical medical reagents for use in nucleic acid-based therapycell therapypharmaceutical preparationsprophylaxis products preparations and other pharmaceutical products preparations and other pharmaceutical products preparations for use in nucleic acid-based therapygene therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases
Classe 42
Scientific and medical researchproduct development and consultancy in the field of biotechnologybiologicsmedical sciencechemistry and biochemistry; Scientific and medical research and product development in the field of pharmaceutics
Classe 44
Medical treatment by gene and nucleic acid deliverygene and nucleic acid transfergene and nucleic acid regulation and gene and nucleic acid modulation for metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesinflammatory and auto-immune diseasesvascular disordersinherited disordersgenetic disorders and single gene disorders; consultancy in the field of pharmaceutics
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/01/2025
FIMP
FINAL DISPOSITION PROCESSED
01/01/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/10/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
09/04/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/04/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/04/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/03/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
13/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/01/2024
PUBO
PUBLISHED FOR OPPOSITION
23/01/2024
GPNX
NOTIFICATION PROCESSED BY IB
22/01/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/01/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/12/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
12/12/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/12/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
12/12/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/12/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/12/2023
RFNT
REFUSAL PROCESSED BY IB
22/07/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
27/06/2023
RFRR
REFUSAL PROCESSED BY MPU
27/06/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
20/05/2023
CNRT
NON-FINAL ACTION WRITTEN
19/05/2023
DOCK
ASSIGNED TO EXAMINER
18/05/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/04/2023
MAFR
APPLICATION FILING RECEIPT MAILED
18/10/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/10/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/10/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VECTAB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.